Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer
Yingpu Li, Yue Liang, Sifan Zhang, Xinxuan Wang, Yu-nan Zhu, Jianyu Liu, He Ren, Wenhao Jiang, Jingxuan Wang, Zhiren Zhang, Tong Liu
Abstract
Anti -PD-1/PD-L1 treatment has achieved durable responses in TNBC patients, whereas a fraction of them showed non-sensitivity to the treatment and the mechanism is still unclear. Pre- and post-treatment plasma samples from triple negative breast cancer (TNBC) patients treated with immunotherapy were measured by tandem mass tag (TMT) mass spectrometry. Public proteome data of lung cancer and melanoma treated with immunotherapy were employed to validate the findings. Blood and tissue single-cell RNA sequencing (scRNA-seq) data of TNBC patients treated with or without immunotherapy were analyzed to identify the derivations of plasma proteins. RNA-seq data from IMvigor210 and other cancer types were used to validate plasma proteins in predicting response to immunotherapy. A random forest model constructed by FAP, LRG1, LBP and COMP could well predict the response to immunotherapy. The activation of complement cascade was observed in responders, whereas FAP and COMP showed a higher abundance in non-responders and negative correlated with the activation of complements. scRNA-seq and bulk RNA-seq analysis suggested that FAP, COMP and complements were derived from fibroblasts of tumor tissues. We constructe an effective plasma proteomic model in predicting response to immunotherapy, and find that FAP + and COMP + fibroblasts are potential targets for reversing immunotherapy resistance. • Plasma proteomic features FAP, LRG1, LBP and COMP can effectively predict response to anti -PD-1/PD-L1 immunotherapy. • The activation of complement cascade favors the response to immunotherapy whereas associated with the resistance to chemoresistance. • High abundance of ECM components is enriched in non-responders received anti -PD-1/PD-L1 immunotherapy. • Tumor tissue-derived FAP and COMP are potential targets for overcoming anti -PD-1/PD-L1 immunotherapy resistance. • The crosstalk between fibroblasts may compromise the effectiveness of anti -PD-1/PD-L1 immunotherapy.